Pfizer Stock News

Senator Imee Marcos on Sunday said she is outraged at the Department of Health (DOH) for releasing a memorandum that enables the government to dismiss parental consent if a child is willing to be vaccinated. Marcos reminded the DOH that the government should not and cant usurp parental authority. Government cannot usurp parental authority. Parents have the right to decide on the health and safety of their children, Marcos said in a statement. Marcos is referring to the controversial memorandum issued last January 24 stating that the government can act as parens patriae Latin for parent of the nation when a child wants to be vaccinated but parental consent is denied. Stated on Page 6 of the memorandum stated that: In case the parent/guardian refuses to give consent to the vaccination despite the desire and willingness of the minor child to have himself/herself vaccinated, or there are no Persons that may legally exercise parental authority over the child, the State may act as parens patriae and give the necessary consent.

Coronavirus vaccines have been prepared for distribution at a vaccination site in Manila on May 18, 2021. (Ali Vicoy/Manila Bulletin) The Philippines is ready to start its coronavirus disease (COVID-19) vaccination drive for its younger population aged five to 11-years-old starting Monday, Feb. 7. The Pfizer-BioNTech vaccines intended for the said age group were already distributed to the different pediatric vaccination sites, said DOH Undersecretary and National Vaccination Operations Center (NVOC) Chairperson Myrna Cabotaje. “Yes we are ready. Dispatched n[a] kahapon yung mga bakuna (The vaccines were already dispatched yesterday),” said Cabotaje in a text message on Sunday, Feb. 6. “Handang handa na po yung ating mga piling-piling bakuna center para bakunahan [ang] mga anak ninyo (Our select vaccination centers are already prepared to vaccinate your children),” she added. “Ang ibibigay na Pfizer na bakuna ay age-appropriate at binigyan ng EUA ng ating Phil[ippine] FDA [Food and Drug Administration] kaya sigurado tayo sa safety at efficacy/bisa nito (The Pfizer vaccine, that will be administered, is age-appropriate and was given an EUA by our Philippine FDA— so, we are confident in its safety and efficacy),” she furthered.

Pentagon Responds To DoD Whistleblowers'' Claim Of Spiking Disease Rates In The Military After COVID Vaccine Mandate Authored by Enrico Trigoso via The Epoch Times, Three United States military doctors have blown the whistle on documents allegedly from The United States Department of Defense (DoD) that they had access to, which show “skyrocketing rates of disease” since the introduction and mandating of the CCP virus vaccines in armed forces , human rights attorney Leigh Dundas told The Epoch Times. Dundas was recently approached by Dr. Samuel Sigoloff, Special Forces flight surgeon Lt. Col. Peter Chambers, and Aerospace occupational medicine specialist Lt. Col. Theresa Long. They handed documents to Dundas, who appeared recently with attorney Tom Renz in a five-hour hearing organized by Sen. Ron Johnson (R-Wis.) titled “ COVID-19: Second Opinion .” Renz shared some of the numbers related to medical disorders in the U.S. military data with The Epoch Times. The whistleblowers, who are represented by Renz, gave him the data “under penalty of perjury,” he said during the hearing .

The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices met Friday to discuss potential implications of both Pfizer and Modernas shots.

A CDC survey of health-care providers found that 81% of their patients who developed myocarditis after vaccination completely or probably recovered.

Florida continues to see a decline in COVID-19 cases after a surge in infections caused by the omicron variant.

Looking into the current session, Pfizer Inc. (NYSE: PFE ) is trading at $53.10, after a 0.5% drop. Over the past month, the stock decreased by 4.71%, but over the past year, it actually increased by 52.49%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company''s price-to-earnings ratio. Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The … Full story available on Benzinga.com

Long Funeral Homes, Short Life Insurers? Ex-Blackrock Fund Manager Discovers Disturbing Trends In Mortality Four weeks ago , OneAmerica insurance company CEO Scott Davison revealed that they had witnessed '' the highest death rates in the history of this business - not just at OneAmerica'' with a jump of '' 40% over what they were pre-pandemic. '' Interestingly, Davison noted that the majority of deaths are not classified as due to Covid-19. So the CEO in his own words. They are mandating vaccines in the workplace and raising premiums in lower vaccinated counties because they are mistakenly guessing here initially. The premiums will change to higher vaccinated areas as time moves on is my guess. He missed the plot. pic.twitter.com/avjFxkn7su Ed Free Thinker & Oracle (@DowdEdward) January 3, 2022 The implication to many was clear - that the Covid-19 vaccine is linked to the excess mortality, and months of vaccine injury reports were now spilling over to actuarial data - which is beginning to show, among other things, that younger, working-age people began dying in greater numbers as vaccine mandates hit - for a disease which primarily kills older, non-working age individuals.

Valneva and Pfizer plan a three-dose primary series for a phase 3 trial of its Lyme disease vaccine candidate, VLA15

Valneva SE (NASDAQ: VALN ) and Pfizer Inc (NYSE: PFE ) have reported further Phase 2 data for their Lyme disease vaccine candidate, VLA15. The Phase 2 trial, VLA15-221, compared the immunogenicity of VLA15 after administration of two or three primary series doses. In the sub-analysis of adult participants (18-65 years old), VLA15 was immunogenic with both vaccination schedules tested. These data are consistent with the strong immunogenicity profile observed for this age group in Full story available on Benzinga.com

Germany''s expert panel on vaccine use has recommended Novavax Inc''s (NASDAQ: NVAX ) protein-based COVID-19 vaccine for primary immunization for people over 18 years. The advisory group known as STIKO said a booster shot should still be given with an mRNA vaccine, reported Reuters. mRNA technology is behind the two most commonly used COVID-19 vaccines from - Pfizer Inc (NYSE: PFE ) / BioNTech SE (NASDAQ: BNTX ) and Moderna Inc (NASDAQ: MRNA ). Novavax''s COVID-19 vaccine NVX-CoV2373 is Full story available on Benzinga.com

CAPE TOWN, South Africa South Africas Afrigen Biologics has used the publicly available sequence of Moderna Incs mRNA COVID-19 vaccine to make its own version of the shot, which could be tested in humans before the end of this year, Afrigens top executive said on Thursday, February 3. The vaccine candidate would be the first to be made based on a widely used vaccine without the assistance and approval of the developer. It is also the first mRNA vaccine designed, developed and produced at lab scale on the African continent. The World Health Organization (WHO) last year picked a consortium including Afrigen for a pilot project to give poor and middle-income countries the know-how to make COVID vaccines , after market leaders of the mRNA COVID vaccine, Pfizer, BioNTech and Moderna, declined a WHO request to share their technology and expertise. The WHO and consortium partners hope their technology transfer hub will help overcome inequalities between rich nations and poorer countries in getting access to vaccines.

"Ask Halftime" traders answer your questions about specific stocks and ETFs.

At FDA request, Pfizer will make a "rolling submission" of its emergency use authorization request for a two-dose vaccine for kids 6 months through 4 years, with information on a planned third dose to come later.

Revenue from operations rose to Rs 675.9 crore for the period under review as compared with Rs 593.49 crore in the same period of 2020-21 fiscal, Pfizer Ltd said in a regulatory filing.